RECOMBINANT WEST NILE VIRUS VACCINE ADJUVANTED WITH SLA-LSQ
Award amount
$2,997,218Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HAWAII BIOTECH, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ECJKEEFL4L51
- Solicitation number
- PHS-2022-1
- Topic code
- 105
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Chikungunya Recombinant Subunit Vaccine
- Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
- Novel TLR-4 Agonists as Vaccine Adjuvants
- Chikungunya Recombinant Subunit Vaccine
- Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Multi-omic CSF Assay for the Diagnosis of Brain Cancers
- A unified eligibility application and determination system to increase Ryan White linkage to care and retention in care by reducing structural barriers and facilitating client engagement
- Novel carriers for enhanced oligonucleotide permeability through the blood-brain barrier
- PEP/PrEP via Pharmacist-Prescribing Implementation (PEPPI)
- Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
Research funding history
103 SBIR/STTR records share this UEI (1983–2024). Reported award amounts total $40,917,853. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture